Companies Dominating the Cancer Diagnostics Landscape
- Siemens Healthcare Gmbh
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GE Healthcare
- Abbott
- Becton, Dickinson & Company
- Illumina Inc.
- Hologic Inc.
- F.Hoffman-La Roche
- Qiagen NV
- Phillips Healthcare
- CR Bard Inc.
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Biocartis SA
- Biocare Medical LLC
- Cancer Genetics Inc.
- Myriad Genetics
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cancer diagnostics is estimated at USD 119.89 billion.
Cancer Diagnostics Market size was over USD 113.89 billion in 2024 and is poised to exceed USD 248.95 billion by 2037, growing at over 6.2% CAGR during the forecast period i.e., between 2025-2037.
North America industry is anticipated to account for largest revenue share by 2037, backed by increasing geriatric population, rising research and development initiatives by the government, increasing cancer cases among the population and need for evidence based treatment for cancer.
The major players in the market are Siemens Healthcare Gmbh, GE Healthcare, Abbott, Becton, Dickinson & Company, Illumina Inc., Hologic Inc., F.Hoffman-La Roche, Qiagen NV, Phillips Healthcare, CR Bard Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., Biocartis SA, Biocare Medical LLC, Cancer Genetics Inc., Myriad Genetics, and others.
